{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:51:29Z","timestamp":1649195489923},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.transproceed.2010.11.020","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T02:56:11Z","timestamp":1303181771000},"page":"826-832","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Efficacy and Safety of Mycophenolate Sodium in Patients With De Novo and Maintenance Renal Transplantation: Results of a Multicenter, Prospective, Observational Study"],"prefix":"10.1016","volume":"43","author":[{"given":"T.","family":"Arinsoy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Uslu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Mir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Titiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gonenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Apaydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kacar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Guvence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Turkmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2010.11.020_bib1","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","article-title":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2010.11.020_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.11.020_bib3","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1097\/00007890-200006150-00033","article-title":"Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection","volume":"69","author":"Ojo","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.11.020_bib4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","article-title":"Adverse gastrointestinal effects of mycophenolate mofetil: etiology, incidence and management","volume":"24","author":"Behrend","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.transproceed.2010.11.020_bib5","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2010.11.020_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1399-0012.2003.00026.x","article-title":"The impact of mycophenolate dosing patterns on clinical outcomes after renal transplantation","volume":"17","author":"Pelletier","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib7","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation","volume":"68","author":"van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.11.020_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1432-2277.2004.tb00394.x","article-title":"Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil","volume":"17","author":"Hardinger","year":"2004","journal-title":"Transplant Int"},{"key":"10.1016\/j.transproceed.2010.11.020_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1399-0012.2005.00421.x","article-title":"Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcome and healthcare costs in renal transplant recipients","volume":"19","author":"Tierce","year":"2005","journal-title":"Clinical Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib10","first-page":"242","article-title":"Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant","volume":"5","author":"Schnitzler","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1399-0012.2004.00318.x","article-title":"Enteric coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil","volume":"19","author":"Arns","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib12","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.5.6.1333","article-title":"Review of the immunosuppressant enteric-coated mycophenolate sodium","volume":"5","author":"Budde","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.transproceed.2010.11.020_bib13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"(ERL B301 Study Group): Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib14","first-page":"112","article-title":"Long term administration of enteric-coated mycophenolate sodium (EC-MPS, myfortic \u00ae) is safe in kidney transplant patients","volume":"66","author":"Salvadori","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2010.11.020_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","article-title":"(ERL B302 Study Group): Enteric-coated mycophenolate sodium can be safely administrated in maintenance renal transplant patients: results of 1-year study","volume":"24","author":"Budde","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib16","first-page":"103","article-title":"Long-term safety and efficacy of the conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic \u00ae)","volume":"66","author":"Budde","year":"2006","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.transproceed.2010.11.020_bib17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.transproceed.2004.07.031","article-title":"Myproms Latam Study Group: Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study","volume":"36","author":"Abbud-Filho","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib18","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/01.tp.0000209411.66790.b3","article-title":"Patient-reported gastrointestinal symptom burden and health-related quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium","volume":"81","author":"Chan","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.11.020_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.transproceed.2004.01.037","article-title":"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study","volume":"36","author":"Nashan","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib20","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1345\/aph.1D063","article-title":"Enteric-coated mycophenolate sodium","volume":"37","author":"Gabardi","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.transproceed.2010.11.020_bib21","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.transproceed.2006.08.085","article-title":"Renal transplant patients with gastrointestinal intolerability to mycophenolate mofetil: conversion to enteric-coated mycophenolate sodium","volume":"38","author":"Calvo","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.transproceed.2006.02.125","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study","volume":"38","author":"Vogt","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transproceed.2006.10.216","article-title":"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international multicenter studies","volume":"39","author":"Pietruck","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1399-0012.2007.00685.x","article-title":"Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamine and microemulsion cyclosporine protocol","volume":"21","author":"Pelletier","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib25","first-page":"A2156","article-title":"Improved health related quality of life (HRQoL) in renal transplant patients suffering from gastrointestinal (GI) complaints when converted from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS)","volume":"10","author":"Chan","year":"2005","journal-title":"Nephrology"},{"key":"10.1016\/j.transproceed.2010.11.020_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00007890-200407271-01231","article-title":"Safety and tolerability of myfortic\u00ae in combination with steroids and two regimen of Neoral\u00ae in de novo kidney transplant recipients: 6 months interim results","volume":"78","author":"Rostaing","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2010.11.020_bib27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.transproceed.2004.12.020","article-title":"Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients","volume":"37","author":"Massari","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib28","unstructured":"Gir\u00f3n F, Gonc, alves LF, Hern\u00e1ndez E, et al: Safety of the conversion from MMF to mycophenolate sodium (myfortic) enteric- coated tablets in stable renal transplant patients. Three months interim analysis. Presented at XVII Congreso de Transplante de America Latina y E1 Caribe, Cuzco, Peru, May 20\u201323, 2003"},{"key":"10.1016\/j.transproceed.2010.11.020_bib29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.transproceed.2007.03.064","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12- month multicenter, open-label, prospective studies","volume":"39","author":"Legendre","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib30","first-page":"191","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: results of a 12-month multicentre, open-label, prospective study","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2010.11.020_bib31","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.transproceed.2006.08.119","article-title":"Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients","volume":"38","author":"Rostaing","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2010.11.020_bib32","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1016\/j.transproceed.2006.08.118","article-title":"Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine","volume":"38","author":"Nashan","year":"2006","journal-title":"Transplant Proc"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134510017276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134510017276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T11:50:10Z","timestamp":1543837810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134510017276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0041134510017276"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2010.11.020","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}